Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

September 27, 2017 at 8:48 am

Journal of Infectious Diseases June 1, 2017 V.215 N.11 P.1711–1719

Li-Min Huang; Thanyawee Puthanakit; Chiu Cheng-Hsun; Tang Ren-Bin; Tino Schwarz …

Background.

We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9–14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15–25 years. Here, we report the results at study end (month 36 [M36]).

Methods.

Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); women received 3 doses at months 0, 1, and 6 (3D_M0,1,6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D_M0,6 versus 3D_M0,1,6; 2D_M0,12 versus 3D_M0,1,6; and 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, T cells, B cells, and safety.

Results.

At M36, the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune responses up to M36.

Conclusions.

Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclusion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls.

PDF

https://watermark.silverchair.com/api/watermark?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAdMwggHPBgkqhkiG9w0BBwagggHAMIIBvAIBADCCAbUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMHBm-s0-bOn6fFpqaAgEQgIIBhsdQl7bghVC7CzZ_-MH5pSD2jsEI2z15neP5mFgk4ey6GTVkywBP40px9H0HDjdX6x9-A_bXJ9wArz9Miy9FqUGQaJbJ6F3Y1xzq_h_LScFksUF5Hjb-c3rIccSwd0TeeX1Rn30mMMMDpHyXRfoXkY4Y0ejcCDlA8hNtXRZ4dvo_fE6Qc5cabq2wkY2u-le2vWqueKnAnDp2yty_vjTR3LDD5JMmY1LdENH-ZKAZfl3DlA9EvoL7W4Jc8SDseSmQ6zjtsI7TqpA0X4gHKzrlEB-QDv7Zu1MURga0NYzYTOhroGquIrTt_gcxwiuIDTyRTVsSHlkyDLZBt8b4A5vX4f2uYR9hVuOpXEqi2MEccjlqi9O_yl-Mg5OhbrXjw1RxVy6BYY4iq8B_upKE5h–LC3H-rrN9TCqJbUmPF73dRI5QsZoDRnGilZFwjLvGZyn2r6p9RSx_pyjzA_1Bueg0lagLoQyoqzyODfWrhHyxmg_8IyzEo21pC9SblCDbAnJWablYjOFAA

Advertisements

Entry filed under: Inmunizaciones, REPORTS, Update.

Preventing Methicillin-Resistant Staphylococcus aureus (MRSA) Disease in Urban US Hospitals—Now for the Hard Part: More Evidence Pointing to the Community as the Source of MRSA Acquisition Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virus–Infected Patients in Brazil


Calendar

September 2017
M T W T F S S
« Aug   Oct »
 123
45678910
11121314151617
18192021222324
252627282930  

Most Recent Posts


%d bloggers like this: